SCM
PVLA

Superstring Capital Management’s Palvella Therapeutics PVLA Stock Holding History

Superstring Capital Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-25,469
Closed -$2.67M – 57
2025
Q4 		$2.67M Buy
+25,469
New +$2.17M 1.43% 24

Other funds holding PVLA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Superstring Capital Management's PVLA Position: Q1 2026 in Review

Superstring Capital Management sold out of Palvella Therapeutics (PVLA) in Q1 2026, closing a stake of 25,469 shares — an estimated $2.67M sold.

Superstring Capital Management first reported a position in PVLA in Q4 2025 and held it in 1 quarter. The position peaked at $2.67M in Q4 2025. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

  • Superstring Capital Management reported no remaining Palvella Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Superstring Capital Management sold 25,469 Palvella Therapeutics shares in Q1 2026, an estimated $2.67M.
  • Superstring Capital Management first reported a position in Palvella Therapeutics in Q4 2025 and held it in 1 quarter.
  • Superstring Capital Management's Palvella Therapeutics position peaked at $2.67M in Q4 2025.
  • 180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on Superstring Capital Management's 13F filing for Q1 2026, filed 14 May 2026.